Bitterroot Bio Announces Appointment of Georgette Verdin as Chief People Officer and Sherwin Chen as Chief Legal Officer and Corporate Secretary
June 04, 2024 08:00 ET
|
Bitterroot Bio
PALO ALTO, Calif. and NEEDHAM, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Bitterroot Bio, a pioneering biotechnology company focused on developing innovative medicines in the field of...
Bitterroot Bio Announces Dosing of First Participants in a Phase 1, First-in-Human Study of BRB-002 in Healthy Volunteers
April 29, 2024 08:00 ET
|
Bitterroot Bio
PALO ALTO, Calif. and MELBOURNE, Australia, April 29, 2024 (GLOBE NEWSWIRE) -- Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, today announced that the...
Bitterroot Bio and Biotheus Announce Research Collaboration to Develop Bispecific Proteins in Cardio-Immunology
February 26, 2024 19:00 ET
|
Bitterroot Bio
PALO ALTO, Calif., and ZHUHAI, China, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Bitterroot Bio, a leader in innovative treatments for cardiovascular diseases, and Biotheus, a pioneer in monoclonal and...
Bitterroot Bio to Present Preclinical Research at American Heart Association Conference
October 30, 2023 08:00 ET
|
Bitterroot Bio
PALO ALTO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Bitterroot Bio, a biotechnology company focused on developing novel immunotherapies in cardiovascular disease, has been selected to present...
Bitterroot Bio Launches Out of Stealth with $145 Million Series A Financing to Develop Transformative Medicines in Cardio-immunology
June 07, 2023 08:00 ET
|
Bitterroot Bio
Founders, Executive Team, and Advisors are recognized scientific and clinical pioneers in the fields of immunology and cardiology Series A financing co-led by ARCH Venture Partners and Deerfield...